Interestingly, CD8+ and CD25+ could be such markers, since TILs are associated with improved distant metastases-free survival as well as increased rates of pathological complete response (pCR) after neoadjuvant trastuzumab and chemotherapy in patients with HER2-positive breast tumors [6, 32]. Here, CD8A is linked to breast neoplasm.